{
    "ticker": "CRNX",
    "name": "Crinetics Pharmaceuticals, Inc.",
    "description": "Crinetics Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for endocrine diseases and disorders. Founded in 2008 and headquartered in San Diego, California, Crinetics is dedicated to addressing unmet medical needs in the field of endocrinology. The company's innovative approach leverages a deep understanding of hormone signaling pathways to develop treatments that improve patient outcomes. Crinetics' lead product candidate, paltusotine, is a novel oral therapy aimed at treating acromegaly, a rare hormonal disorder caused by excess growth hormone. The company is also advancing a robust pipeline of other candidates targeting various endocrine disorders, including Cushing's disease and neuroendocrine tumors. Crinetics is committed to advancing science and improving patients' lives through groundbreaking research and development, with a focus on precision medicine. With a strong team of experienced professionals and a commitment to collaboration, Crinetics aims to be a leader in the endocrine therapeutics space.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "San Diego, California, USA",
    "founded": "2008",
    "website": "https://www.crinetics.com",
    "ceo": "Terry Coelho",
    "social_media": {
        "twitter": "https://twitter.com/Crinetics",
        "linkedin": "https://www.linkedin.com/company/crinetics-pharmaceuticals/"
    },
    "investor_relations": "https://investors.crinetics.com",
    "key_executives": [
        {
            "name": "Terry Coelho",
            "position": "CEO"
        },
        {
            "name": "Scott Struthers",
            "position": "Founder and Chief Scientific Officer"
        }
    ],
    "product_categories": [
        {
            "category": "Product Candidates",
            "products": [
                "Paltusotine",
                "CRN04894",
                "CRN01941"
            ]
        }
    ],
    "seo": {
        "meta_title": "Crinetics Pharmaceuticals, Inc. | Innovative Endocrine Therapies",
        "meta_description": "Learn about Crinetics Pharmaceuticals, Inc., a leader in developing innovative therapies for endocrine diseases, including acromegaly and Cushing's disease.",
        "keywords": [
            "Crinetics",
            "Endocrine Disorders",
            "Biopharmaceuticals",
            "Paltusotine",
            "Acromegaly",
            "Cushing's Disease"
        ]
    },
    "faq": [
        {
            "question": "What is Crinetics Pharmaceuticals known for?",
            "answer": "Crinetics Pharmaceuticals is known for developing novel therapies for endocrine diseases, particularly their lead candidate paltusotine for acromegaly."
        },
        {
            "question": "Who is the CEO of Crinetics Pharmaceuticals?",
            "answer": "Terry Coelho is the CEO of Crinetics Pharmaceuticals, Inc."
        },
        {
            "question": "Where is Crinetics Pharmaceuticals headquartered?",
            "answer": "Crinetics Pharmaceuticals is headquartered in San Diego, California, USA."
        },
        {
            "question": "What are Crinetics' main product candidates?",
            "answer": "Crinetics' main product candidates include paltusotine, CRN04894, and CRN01941."
        },
        {
            "question": "When was Crinetics Pharmaceuticals founded?",
            "answer": "Crinetics Pharmaceuticals was founded in 2008."
        }
    ],
    "competitors": [
        "REGN",
        "VRTX",
        "AMGN"
    ],
    "related_stocks": [
        "MRNA",
        "GILD",
        "BMY",
        "ABBV"
    ]
}